Abstract
Currently, the growing diagnosis of neoplasms in the clinical routine requires effective therapies to guarantee greater patient survival; among the main drugs used to achieve this goal, we highlight the doxorubicin, a chemotherapy used in innumerable antineoplastic therapy protocols. Its effectiveness has been well described for years, but like any drug, adverse effects are expected and c…